Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Corcept Therapeutics (CORT) EBIAT (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed EBIAT for 16 consecutive years, with -$31.8 million as the latest value for Q1 2026.

  • For Q1 2026, EBIAT fell 254.58% year-over-year to -$31.8 million; the TTM value through Mar 2026 reached $47.3 million, down 64.67%, while the annual FY2025 figure was $99.7 million, 29.43% down from the prior year.
  • EBIAT hit -$31.8 million in Q1 2026 for Corcept Therapeutics, down from $24.3 million in the prior quarter.
  • Across five years, EBIAT topped out at $47.2 million in Q3 2024 and bottomed at -$31.8 million in Q1 2026.
  • Average EBIAT over 5 years is $24.5 million, with a median of $27.5 million recorded in 2023.
  • Year-over-year, EBIAT skyrocketed 88.87% in 2023 and then tumbled 254.58% in 2026.
  • Corcept Therapeutics' EBIAT stood at $16.6 million in 2022, then surged by 88.87% to $31.4 million in 2023, then fell by 1.94% to $30.7 million in 2024, then dropped by 21.0% to $24.3 million in 2025, then plummeted by 230.77% to -$31.8 million in 2026.
  • According to Business Quant data, EBIAT over the past three periods came in at -$31.8 million, $24.3 million, and $19.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.